asset beta debt beta

In 3 of the last 4 rebounds in the market since 1982, thanks to equity has slowed to a double digit pace in a year, 2 after the initial meeting. Now, the stock dividend have an added attraction because they offer an attractive alternative to the CDs that pay almost no interest at all, and long-term bonds to pay a bit more, but I leave you for inflation. Business value established in stable industries have generally shown better long-term investment. Before S & P cut Pfizer (PFE) ratings to 'AA' from 'AAA' October 16, 2009, there are 5 companies with AAA ratings: Automatic Processing Data (ADP), Johnson & Johnson (JNJ), ExxonMobil (XOM) and Microsoft (MSFT). In other words, 2 of 5 companies were health care. Large companies health covering health care, that plans for the stock of UnitedHealth Group (UNH) in my article of October 27. The following are health companies in other sub-sectors health care sector, in order of performance: Name (Symbol) Industry P / EP Advance / E Yield Eli Lilly Co. (LLY) Drug Manu. N / A 8 5.2% BRISTOL-MYERS SQ (BMY) Drug Manu. 13 12 4.8% GlaxoSmithKline (GSK) Drug Manu. 13 12 4.6% MERCK CO INC (MRK) Drug Manu. 10 10 4.2% SANOFI-AVENTIS SA (SNY) Drug Manu. N / A 8 3.6% Pfizer Inc. (PFE) Drug Manu. 15 8 3.4% Johnson & Johnson (JNJ) Drug Manu. 14 13 3.1% NOVARTIS AG ADS (NVS) Drug Manu. 17 13 3.1% ABBOTT LAB (ABT) Drug Manu. ALCON 15 13 2.9% Inc. (ACL) Medical Instru 23 20 2.6% AstraZeneca PLC (AZN) Drug Manu. 9 8 2.5% Baxter International Inc. (BAX) Medical Instru 15 13 1.9% MEDTRONIC INC (MDT) Medical Devices 25 12 1.9% Novo Nordisk AS (NVO) Drug Manu. 18 16 1.1% Teva Pharmaceutical (TEVA) Drug Manu. 12 0.9% 48 Amgen (AMGN) Biotechnology 12 11 0.0% Gilead Sciences (GILD) Biotechnology 18 15 0.0% Average n / a 18 12 8 first companies listed above to obtain more than 3% of all major drug manufacturers. Some of that have a single digit forward P / is. H1N1 vaccine could benefit from leaders such as Novartis (NVS), Sanofi-Aventis (SNY) and AstraZeneca (AZN). On November 25, Health officials have said that the U.S. see a disturbing trend of serious bacterial infections in pigs sick with the flu especially among young adults normally are not vulnerable to them. In addition to the pending reform of the health care, a common problem that is expensive "Big Pharma" is that there are patents expire between 2010 and 2012. However, this industry has tried to boost growth through acquisitions, including trafficking of blockbusters. The pharmaceutical giants also aim at several biotechnology companies to build their pipeline. The Biotechnology Biotechnology offers probably the best level of innovation in industries health. Its P / E is low. For example, Amgen (AMGN) 's P / E is only 12. Although my most important assets are boring blue chip dividend, I too allocates a small portion of my portfolio on promising small caps. Organic products from China (CBPO.OB) is one of the leading plasma-based biopharmaceutical companies in China. For the first nine months of 2009, total revenue was 81 million, up 142% over 2008. It has $ 50 billion in cash and low debt. However, listed on the OTC Bulletin Board, the volatility of share price was extreme. He also liabilities arising that could affect future earnings. Top 10 HealthCare ETF (based on net assets) Fund Name (Ticker) Growth rate of net assets (GBR) Health Care Select Sector SPDR (XLV) 1.93B 8% Pharmaceutical HOLDRs (PPH) 6% iShares 1.52B Nasdaq Biotechnology (IBB) 1.35B 16% Biotech HOLDRs (BBH) 728m 13% iShares Dow Jones U.S. Health (IYH) 582m 9% Vanguard Health Care ETF (VHT) iShares 538m 10% S & P Global Healthcare (ixj) 439M 9% SPDR S & P Biotechnology (Xbi) 371m 21% iShares Dow Jones U.S. Medical Devices (IHI) 269M 13% PowerShares Dynamic Biotech & Gen (PBE) Conclusion 183M 17% during the relatively benign period of 20 years before 2008, most of the considerable backlog through volatility of short, looking very attractive to investors due to the positive performance of recent years. It was this party was increasingly volatile pain in so short that you created in the current slowdown, according to CFA Digest November 2009 Issue. To buy, after a drop of 40% is not a bet safe for investors. The markets may continue to decline, and often have no difficulty in reaching the bottom at 75% below the peak. Recent examples in 1989, Japan's Nikkei, NASDAQ 2000, 2007 in the Chinese market in 2008 and oil / natural gas prices. So, if investors think the environment will still unstable, seek stocks with less sensitivity to volatility. Even if they make less profit for you on the road, they lose less in the way back to down. With its advanced P / E of 12 and average beta of 0.69, the health care could be a great defense sector. For those who need a stable income, large pharmaceutical companies may be a good choice. Disclosure: I've long position in the HPP and CBPO.OB. The data are from Yahoo Finance, dated 27 November 2009. For more information about how to invest in the stock market, please visit our trading course now! About the Author:

Hao Jin is a Chartered Financial Analyst (CFA) and has over 15 years experience as an investor. He graduated from SUNY Stony Brook’s Harriman School for Management and Policy in 1993. Check out his blog, PointFinancialAdvisor

Article Source: ArticlesBase.com – Invest in HealthCare!